Crinetics Pharmaceuticals, Inc.
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Checking your notes…
Rule 10b5-1 Trading Plans
The following members of our Board of Directors and/or officers adopted, modified, or terminated a trading arrangement that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c):
| Name | Title of Director or Officer | Action | Date of Action | Duration of Plan | Total Shares of Common Stock to be Sold |
|---|---|---|---|---|---|
| Dana Pizzuti | Chief Medical and Development Officer | Termination of 10b5-1 plan | May 20, 2025 | January 3, 2025 - December 31, 2025 | Up to 70,000 shares |
| Dana Pizzuti | Chief Medical and Development Officer | Adoption of 10b5-1 plan | May 21, 2025 | August 20, 2025 - September 2, 2026 | Up to 96,492 shares |
| Isabel Kalofonos | Chief Commercial Officer | Adoption of 10b5-1 plan | June 7, 2025 | January 1, 2026 - December 19, 2026 | Up to 12,500 shares |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.